Biogen Inc. (BIIB) was upgraded to a "buy" by TheStreet's Quant Ratings service on Wednesday. This biotech name has made a chart that could be challenging to many traders and investors. Let's drill down and see if an easier approach to the long side can be found.
More from Stocks
In one week we should know whether the Dec. 15 tariffs will increase as planned.
Samsung's Galaxy S11 will reportedly have a very powerful rear-camera system. And rivals aren't standing still, either.
Investors typically look to food stocks for stable profits and reliable dividends year in and year out.